Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • Middle East
    موقعك
  • Request Information

    800 50342
    طلب معلومات 800 50342
  • عربي
  • Request Information

    800 50342
    طلب معلومات 800 50342
Middle EastMiddle East
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • POC
      • WES
      • NACE
      • SAT
    • Patients
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • POC
      • WES
      • NACE
      • SAT
  • Diagnostics
  • About Us
    • Igenomix Research
    • About Igenomix
  • Our blog
  • Clinic Portal
  • ACADEMY
Genomics Precision Diagnostic > Gene Analysis > CMA

CMA – Chromosomal Microarray

Chromosomal microarray analysis is the gold standard for the detection of deletions and duplications along the whole genome.
Overview
Reporting
Methodology
Sample Requirements
Limitations

CMA Overview

  • CMA
  • Application
  • Indication
  • Chromosomal microarray analysis (CMA), also known as array CGH, is a diagnostic test that can detect clinically significant major chromosomal imbalances (aneuploidies) and sub microscopic (microdeletion / microduplication) copy number variations throughout the genome. 
  • Chromosomal microarray analysis is the gold standard for the detection of deletions and duplications along the whole genome.
  • CMA provides submicroscopic  resolution allowing to visualize small regions that karyotyping cannot detect. CMA’s sensitivity relies on the number of the molecular probes used and their genome coverage. The greater the number of probes (180K, 400K, 750K…), the higher their sensitivity.

CMA can detect:

  • Small chromosomal microdeletions and duplications
  • Copy number variations
  • Numerical chromosomal aneuploidy
  • Unbalanced rearrangements
  • Excessive homozygosity – platform dependent
  • Suggestive risk of inheriting recessive disease or imprinting disorders – platform dependent
  • Triploidy and tetraploidy – platform dependent
  • Mosaicism greater than 20-30%
Preconception

CMA can be offered in the pre-conception phase if one or more of the below indications are present:

  • If a previous affected child presents with a normal karyotype or WES, but a genetic condition is suspected..
  • To check whether a copy number variation that was detected in the affected child is de novo or inherited from their parents.

Constitutional karyotyping in both parents is always recommended when a balanced chromosomal rearrangement is suspected (i.e. Recurrent miscarriages, infertility,..) 

Prenatal

CMA is offered prenatally if one or more of the below indications are present:

  • Abnormal fetal ultrasound
  • Abnormal NIPT results indicated an increased risk of a chromosomally abnormal fetus
  • Abnormal high-risk maternal serum screen
  • The parents have a known chromosomal rearrangement, mosaicism or previous aneuploidies
  • The parents have had previous livebirths or stillbirths with chromosomal abnormalities
  • Fetal congenital abnormalities detected with ultrasound or MRI that indicate a significant risk of an unbalanced chromosomal abnormality
  • Apparently balanced inherited rearrangements in a fetus with congenital abnormalities.
  • Apparently balanced de novo rearrangements identified by G-band analysis (karyotype)
  • High risk pregnancies
Post-natal

CMA is offered in childhood or adulthood if one or more of the below indications are present – the chromosomal microarray can be considered as a first line test in the following

  • If an individual or fetus presents with multiple congenital anomalies that are not specific to a well identified genetic syndrome
  • If a karyotype is negative and the individual’s phenotype is indicative of chromosomal aneuploidy.
  • If an individual or fetus present with apparently nonsyndromic developmental delay or intellectual disabilities
  • If an individual presents with autism spectrum disorders
  • If a fetus is malformed or a still birth of unknown aetiology occurs

The CMA can be used in cases where other tests have failed to yield a diagnosis specifically if one or more of the below symptoms or conditions are present

  • Unexplained seizure disorder
  • Growth delay
  • Psychiatric illness
  • Neuromuscular conditions
  • Neuromuscular conditions
  • Skeletal dysplasia
  • Short stature
  • Excessive growth
  • Microcephaly
  • Macrocephaly
Product of Conception
  • CMA can be offered on a product of conception if there was a case of spontaneous abortions.

CMA Reporting & Results

Different types of CMA are available in Igenomix: 

CMA HD (the most sensitive test) 

  • Copy number probes (1.9 million) + SNP (750 K).
  • Whole genome coverage.
  • Can detect regions of low heterozygosity, uniparental disomy (UPD), low level mosciasim and sample heterogeneity.
  • The highest probe density.

CMA 750K (the most cost-effective test) 

  • Copy number probes only (550K) + SNP (200 K) 
  • Emphasis on clinically relevant regions 
  • Identification of regions of excessive homozygosity indicating UPD, may suggest consanguinity and determine candidate genes for further testing 

CMA Sample Requirements

The following sample types are accepted for Igenomix genetic tests. A thorough labelling of the tube with unique identifying information is suggested, incorrect labelling can lead to rejection of the sample. The minimum required information to identify and accept a sample is – Patient’s full name, Date of birth, Gender and Medical Record Number.

  • Maternal blood sample must be sent with all products of conception, CVS and Amnio samples.
  • Precedence will be given to all prenatal samples.

The ‘informed consent’ form and the ‘test requisition from’ (included within the provided kit) must be properly filled-in and signed by the patient and sent with the samples inside the shipping box or by e-mail to the laboratory. Igenomix will send you all the documents needed for the pick-up and transportation of the appropriate kit to our laboratory .

CMA Methodology

Deletions smaller than 50 kb and duplications smaller than 400 kb may not be reviewed. Detected copy number variations (CNVs) are reported when found to have clear or suspected clinical relevance; CNVs devoid of relevant gene content or reported as common findings in the general population may not be reported. Regions of homozygosity are reported when a single LCSH is greater than 8-15 Mb (dependent upon chromosomal location and likelihood of imprinting disorder), or when the total autosomal LCSH proportion is greater than 3% (only autosomal LCSH greater than 3 Mb are considered for this estimate). Genomic linear positions are given relative to NCBI build 37 (hg19).

Test results are interpreted based on the recommendations and guidelines of International Standard of Cytogenomics Arrays (ISCA) as described below:

Positive (Pathogenic and likely pathogenic)
  • A positive result indicates that a copy number variant has been identified in association with the disease phenotype under study. This scenario will allow to provide genetic counselling or personal guidance regarding possible medical treatments, disease progression, reproductive-/prevention-strategies and potential implications for other family members.
Negative:
  • A negative result indicates that no disease-causing copy number variation was identified in the test performed. This does not guarantee that the induvial will be healthy or free from other genetic disorders or medical conditions. Additionally, a negative result does not rule out a genetic cause of the disease nor does it eliminate the risk for future offspring. However, if a negative test result is obtained and the variant in question is known to be present in affected family members, this then rules out a diagnosis of that genetic disorder in the proband. A negative result may be explained by several causes, including limited genetic knowledge and limitations associated to the used methodology.
Inconclusive / Variant of Uncertain Significance (VUS):
  • A finding of a variant of uncertain significance indicates that a copy number variation was detected, but it is currently unknown whether that CNV is associated with a genetic disorder or disease. A variant of uncertain significance is not the same as a positive result and does not clarify whether the proband is at an increased risk to develop a genetic disorder or disease.
  • The change could be a normal genetic variant, or it could be disease-causing. Further analysis may be recommended, including testing both parents as well as other affected and unaffected family members. Sometimes, performing ancillary tests is necessary to prove the phenotype that the proband presents with. Detailed medical records or information from other family members also may be needed to help clarify the result.
  • Result interpretation is based on currently available information in the medical literature, research, and scientific databases. Because the literature, medical and scientific knowledge are constantly changing, new information that becomes available in the future may replace or add to the information that Igenomix used to interpret the results. Re-analysis of the results in previously issued reports considering new evidence is not routinely performed but is available upon request.

CMA Limitations

  • CMA cannot identify:
    • Balanced chromosomal rearrangements (balanced translocations, inversions)
    • Small changes in the sequence of single genes (point mutations)
    • Tiny duplications and deletions of DNA segments within a single gene (Fragile X syndrome, for example)
    • Uniparental disomy (UPD)
    • Methylation alterations
    • Mosaicism less than 20%
    • Complete ploidy





IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility

Inherited diseases prevention

Healthy pregnancy



CAP Accredited laboratory delivering optimal patient care & evolving with innovation in laboratory medicine.

OUR SERVICES

Genetic solutions

For Patients

How to send a sample?

Directory of Test Service

Igenomix Dubai is accredited by EIAC (Emirates international accreditation center) to the ISO 15189 standard for Whole exome sequencing (See scope of accreditation in certificate)

ABOUT US

About Igenomix

Contact

Press and news

Quality

Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  800 50342
  Write us
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
Language

[2019] © Igenomix Privacy policy Quality policy Legal note Cookies policy

Download ERA eBook

Download EMMA eBook

Download ALICE eBook

Download NACE eBook

Download EndomeTRIO eBook

Download PGT-A eBook

Download POC eBook

Download SAT eBook

Download Oncodona eBook

Download Baby Gender eBook

Download WES eBook

Download PGT-M Brochure eBook

Download PGT-M Full Disease List eBook

Download WES Technical Sheet

Download WES eBook

Download WES Instructions eBook

Download SAT Clinical Sheets eBook

Download SAT Instructions eBook

Download Oncodona Brochure eBook

Download Oncodona Instructions eBook

Download PGT-A Technical Sheets eBook

Download PGT-A Brochure eBook

Download PGT-A Mitoscore eBook

Download PGT-A Instructions eBook

Download PGT-M Brochure eBook

Download PGT-M Technical Sheets eBook

Download PGT-M Instructions eBook

Download Baby Gender Step Guide eBook

Download Baby Gender Brochure eBook

Download ERA Technical Sheets eBook

Download ERA Brochure eBook

Download ERA Instructions eBook

Download ERA Instructions eBook

Download EMBRACE Clinical Sheets eBook

Download EMBRACE Brochure eBook

Download EMMA Technical Sheets eBook

Download EMMA Brochure eBook

Download EMMA Instructions eBook

Download ALICE Technical Brochure eBook

Download ALICE FAQ eBook

Download ALICE Infographic Brochure eBook

Download ALICE Brochure eBook

Download ALICE Instructions eBook

Download EndomeTRIO Clinical Sheets eBook

Download EndomeTRIO Brochure eBook

Download EndomeTRIO Infography eBook

Download EndomeTRIO Manual eBook

Download POC Technical Sheets eBook

Download POC Brochure eBook

Download POC Instructions eBook

[gravityform id="59" title="false" description="false" ajax="true"]

Download NACE Clinical Sheets eBook

Download NACE Brochure eBook

Download NACE Instructions eBook

Download My IVF Journey eBook

Download Assisted Reproduction Guide eBook

How can you improve your fertility eBook

  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • POC
      • WES
      • NACE
      • SAT
    • Patients
      • ERA
      • EndomeTRIO
      • EMMA
      • ALICE
      • PGT-A
      • Baby Gender
      • EMBRACE
      • PGT-M
      • POC
      • WES
      • NACE
      • SAT
  • Diagnostics
  • About Us
    • Igenomix Research
    • About Igenomix
  • Our blog
  • Clinic Portal
  • ACADEMY
  • Middle East
    موقعك
  • Languages
    • You need Polylang or WPML plugin for this to work. You can remove it from Theme Options.
  • Clinics' area
We use our own and third-party cookies to improve our services and to show you advertisements related to your preferences by analyzing your browsing habits. If you continue browsing, it is considered that you accept its use.Cookie settingsAccept
Privacy & Cookies Policy

نظرة عامة على الخصوصية

يستخدم هذا الموقع ملفات تعريف الارتباط لتحسين تجربتك أثناء التنقل عبر الموقع. من بين ملفات تعريف الارتباط هذه ، يتم تخزين ملفات تعريف الارتباط المصنفة حسب الضرورة على متصفحك لأنها ضرورية لعمل الوظائف الأساسية للموقع. نستخدم أيضًا ملفات تعريف الارتباط الخاصة بطرف ثالث والتي تساعدنا في تحليل وفهم كيفية استخدامك لهذا الموقع. سيتم تخزين ملفات تعريف الارتباط هذه في متصفحك فقط بموافقتك. لديك أيضًا خيار إلغاء الاشتراك في ملفات تعريف الارتباط هذه. لكن إلغاء الاشتراك في بعض ملفات تعريف الارتباط هذه قد يكون له تأثير على تجربة التصفح لديك.
Necessary
Always Enabled
أي ملفات تعريف ارتباط قد لا تكون ضرورية بشكل خاص لكي يعمل موقع الويب ويتم استخدامها خصيصًا لجمع بيانات المستخدم الشخصية عبر التحليلات والإعلانات والمحتويات الأخرى المضمنة تسمى ملفات تعريف ارتباط غير ضرورية. من الضروري الحصول على موافقة المستخدم قبل تشغيل ملفات تعريف الارتباط هذه على موقع الويب الخاص بك.
Non-necessary
أي ملفات تعريف ارتباط قد لا تكون ضرورية بشكل خاص لكي يعمل موقع الويب ويتم استخدامها خصيصًا لجمع بيانات المستخدم الشخصية عبر التحليلات والإعلانات والمحتويات الأخرى المضمنة تسمى ملفات تعريف ارتباط غير ضرورية. من الضروري الحصول على موافقة المستخدم قبل تشغيل ملفات تعريف الارتباط هذه على موقع الويب الخاص بك.
SAVE & ACCEPT